Celine Roger Dalbert

• Drive WW product development, from the concept to the launch, for the BD MAX and Viper LT Molecular Platforms, for the Bactec and Phoenix Microbiology platforms and for the Surepath Cytology applications. • Involve in future Molecular Platforms development for different market segment. • Build and manage the associated budget totaling >$80.0M for a $700M+ annual revenue business. • Lead, coach and mentor the R&D and Program Management teams. • Evolve the organization and global product development processes to become more proficient and nimble, track and improve performance metrics for the organization. • Assess, recommend, and execute real-time tradeoffs between multiple projects to fully utilize a significant resource pool and associated budget, maximize product features, drive efficiency, and minimize time to market. • Communicate progress on BD’s entire molecular portfolio with the programmatic governance body of the worldwide business, Platform Leadership, and cross-functional leadership. • Influence cross-functional team leadership in a matrix organization. • Work with Operations, Engineering for new product development activities • Work with Regulatory Affairs, Medical/Clinical Affairs and Quality Affairs to develop strategies for clinical trials as well as regulatory bodies’ submission (FDA, China, Japan, ANVISA, CE regulations), experience in PMA, de novo 510(k) and regular 510(k). • Collaborate with World-Wide Business Development team to develop product portfolio strategy including identification of technologies, potential partnership and potential acquisition opportunities • Assess the competition and understand customer needs, identify market trends, technical nuances, and efficiency elements with ability to translate information and leverage across multiple projects

Program Director in Molecular Biology, BD Diagnostics, Baltimore area, MD, USA • Drives WW product development for the BD MAX and Viper LT Molecular Platform, including responsibility for 6 to 8 parallel assays of varying complexity (e.g. technical, regulatory, clinical trial, market release). • Assess, recommends, and executes real-time trade-offs between multiple projects to fully utilize a significant resource pool and associated budget, maximize product features, drive efficiency, and minimize time to market. • Provides innovative solution to difficult problems relating to cross project or cross functional execution. • Selects, coaches and supports development of project leaders. • Communicates progress on BD’s entire molecular portfolio with the programmatic governance body of the worldwide business, Platform Leadership, and cross-functional leadership. • Influences cross-functional team leadership in a matrix organization. • Assesses the competition and understands customer needs, identifies market trends, technical nuances, and efficiency elements with ability to translate information and leverage across multiple projects. • Drives budget built and ASR at the program level. • Manages also sustaining activities for the Molecular diagnostic business unit.

Sr. Director R&D in Molecular Biology and Microbiology at BD Diagnostics Inc. • Management of over 70 Ph.D., M.S. and B.S.-level scientists responsible for designing and delivering assays for the human clinical diagnostics market as well as reagents for the diagnositic in Microbiology (automated ID/AST, culture media) and Management of the associated budget • Active member of the Leadership Team of the Quebec site • Work in collaboration with engineering/software and Manufacturing talent to develop assays on a full-automated molecular platform as well as on an automated platform for ID/AST • Work closely with Regulatory Affairs, Medical Affairs and Quality Affairs to develop strategies for clinical trials as well as regulatory bodies submission (FDA, China, Japan, ANVISA, CE regulations). •Work closely with US and European Business Development team to develop ongoing 5-year product portfolio strategy including identification of technologies, potential partnership and potential acquisition opportunities.

Director R&D in Molecular Biology at BD Diagnostics Inc., Canada • Management of over 65 Ph.D., M.S. and B.S.-level scientists responsible for designing and delivering assays for the human clinical diagnostics market and Management of the associated budget • Active member of the Leadership Team of the Quebec site • Work in collaboration with engineering/software and Manufacturing talent to develop assays on a full-automated molecular platform. • Work closely with Regulatory Affairs, Medical Affairs and Quality Affairs to develop strategies for clinical trials as well as regulatory bodies submission (FDA, China, Japan, ANVISA, CE regulations). •Work closely with US and European Business Development team to develop ongoing 5-year product portfolio strategy including identification of technologies, potential partnership and potential acquisition opportunities.

• Design, conception and development of reagents for an automated system, Tempo® dedicated to quality indicators in food and pharmaceutical industries • Design and Conception of chromogenic culture media (urinary tract infection, a surveillance portfolio including MRSA – ESBL – VRE, a pathogen portfolio including Salmonella, Listeria, Escherichia coli O157:H7, Campylobacter) • Scientific, technical and staff management • Partcipation ofscientific external collaborations with academic and industrial teams in the field of chemistry of enzymatic substrates, • Co-inventor of more than 10 patents